297 related articles for article (PubMed ID: 34697563)
1. The Expression and Function of Circadian Rhythm Genes in Hepatocellular Carcinoma.
Jiang Y; Shen X; Fasae MB; Zhi F; Chai L; Ou Y; Feng H; Liu S; Liu Y; Yang S
Oxid Med Cell Longev; 2021; 2021():4044606. PubMed ID: 34697563
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Circadian Clock Genes as Significant Clinic Factor in the Tumorigenesis of Hepatocellular Carcinoma.
Liang Y; Wang S; Huang X; Chai R; Tang Q; Yang R; Huang X; Wang X; Zheng K
Comput Math Methods Med; 2021; 2021():8238833. PubMed ID: 34745328
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
4. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.
Han LL; Lv Y; Guo H; Ruan ZP; Nan KJ
World J Gastroenterol; 2014 Aug; 20(30):10249-61. PubMed ID: 25132742
[TBL] [Abstract][Full Text] [Related]
5. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
[TBL] [Abstract][Full Text] [Related]
6. The significance of exosomes in the development and treatment of hepatocellular carcinoma.
Li X; Li C; Zhang L; Wu M; Cao K; Jiang F; Chen D; Li N; Li W
Mol Cancer; 2020 Jan; 19(1):1. PubMed ID: 31901224
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
10. The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention.
Zou H; Shao CX; Zhou QY; Zhu GQ; Shi KQ; Braddock M; Huang DS; Zheng MH
Expert Rev Gastroenterol Hepatol; 2016; 10(3):331-40. PubMed ID: 26558504
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
[No Abstract] [Full Text] [Related]
12. Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells.
Qiu S; Zhong C; Zhao B; Li G; Wang J; Jehan S; Li J; Zhao X; Li D; Sui G
Biochim Biophys Acta Gen Subj; 2021 Jul; 1865(7):129911. PubMed ID: 33862123
[TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication.
Lin YH; Wu MH; Yeh CT; Lin KH
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477236
[TBL] [Abstract][Full Text] [Related]
14. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
16. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.
Scaggiante B; Kazemi M; Pozzato G; Dapas B; Farra R; Grassi M; Zanconati F; Grassi G
World J Gastroenterol; 2014 Feb; 20(5):1268-88. PubMed ID: 24574801
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia disrupts the expression levels of circadian rhythm genes in hepatocellular carcinoma.
Yu C; Yang SL; Fang X; Jiang JX; Sun CY; Huang T
Mol Med Rep; 2015 May; 11(5):4002-8. PubMed ID: 25591621
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
